0001209191-22-031791.txt : 20220525
0001209191-22-031791.hdr.sgml : 20220525
20220525090908
ACCESSION NUMBER: 0001209191-22-031791
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220523
FILED AS OF DATE: 20220525
DATE AS OF CHANGE: 20220525
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fletcher Aaron G.L.
CENTRAL INDEX KEY: 0001789490
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38327
FILM NUMBER: 22959319
MAIL ADDRESS:
STREET 1: 40 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cue Biopharma, Inc.
CENTRAL INDEX KEY: 0001645460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473324577
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
BUSINESS PHONE: 617-949-2680
MAIL ADDRESS:
STREET 1: 40 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
FORMER COMPANY:
FORMER CONFORMED NAME: Imagen Biopharma, Inc.
DATE OF NAME CHANGE: 20150617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-23
0
0001645460
Cue Biopharma, Inc.
CUE
0001789490
Fletcher Aaron G.L.
C/O CUE BIOPHARMA INC.
40 GUEST STREET
BOSTON
MA
02135
1
0
0
0
Common Stock
2022-05-23
4
P
0
150000
3.52
A
885000
I
See footnote
Common Stock
2022-05-24
4
P
0
55000
3.34
A
940000
I
See footnote
Common Stock
165000
D
Common Stock
8867
I
By Spouse
The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.31 to $3.62. The price reported in Column 4 is a weighted average price.
The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.21 to $3.52. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Cue Biopharma, Inc., any stockholder of Cue Biopharma, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3).
/s/ Aaron Fletcher by Colin Sandercock, attorney-in-fact
2022-05-25